Amalgamated Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Amalgamated Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.39M	Buy	+18,016	New	+$1.51M	0.01%	1049

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Amalgamated Financial's BMRN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2022: 18,016 shares worth $1.39M. The stake represents 0.01% of the portfolio and ranks #1049 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Amalgamated Financial held 18,016 shares of BioMarin Pharmaceuticals worth $1.39M as of Q1 2022.
BioMarin Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
BioMarin Pharmaceuticals made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1049 holding.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.